A phase 1b randomized, multicenter, dose-determination trial published in Frontiers in Pediatrics evaluated zelpultide alfa—an investigational recombinant human surfactant protein D—in preterm neonates at high risk of bronchopulmonary…
Daniele De Luca discusses zelpultide alfa in neonates at high risk of bronchopulmonary dysplasia development
